Article Details

Disitamab vedotin shows promise in HER2+ metastatic urothelial carcinoma - Urology Times

Retrieved on: 2023-12-07 20:20:14

Tags for this article:

Click the tags to see associated articles and topics

Disitamab vedotin shows promise in HER2+ metastatic urothelial carcinoma - Urology Times. View article details on hiswai:

Excerpt

Guo is the vice president of clinical oncology at Peking University Cancer Hospital & Institute in Beijing, China. The initial phase 2 trial (RC48- ...

Article found on: www.urologytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo